e-learning
resources
Vienna 2009
Monday, 14.09.2009
Severe asthma and its treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
P. Magyar, C. Peckitt, R. Maykut, G. Peachey (Budapest, Hungary; West Sussex, United Kingdom; East Hanover, United States Of America)
Source:
Annual Congress 2009 - Severe asthma and its treatment
Session:
Severe asthma and its treatment
Session type:
E-Communication Session
Number:
1870
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Magyar, C. Peckitt, R. Maykut, G. Peachey (Budapest, Hungary; West Sussex, United Kingdom; East Hanover, United States Of America). Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma. Eur Respir J 2009; 34: Suppl. 53, 1870
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Treatment and outcomes in patients with asthma and allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005
Inflammatory profile of patients with allergic asthma & rhinitis
versus
patients with allergic rhinitis alone
Source: Annual Congress 2007 - Mechanisms of inflammation in asthma and rhinitis - from cell cultures to patients
Year: 2007
The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004
The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis
Source: Eur Respir J 2004; 24: 330
Year: 2004
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Omalizumab decreases IgE production in patients with severe allergic asthma
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 663s
Year: 2006
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab, a novel therapy for severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept